Oruka Therapeutics stock surges as ORKA-001 psoriasis trial success puts $1.1bn biotech strategy to the test
Read More Pharma Industry News Serapha Bio’s gene-editing breakthrough raises stakes for $200m Boundless Bio merger Serapha Bio's SERP-01 gene-editing results strengthen its Boundless Bio merger outlook. Explore the $200M financing and clinical risks. bySoujanya RaviOctober 28, 2026